Immunogenicity of high-dose influenza vaccination in patients with primary central nervous system malignancy.

ABSTRACT:

Background

For cancer patients, rates of influenza-associated hospitalization and death are 4 times greater than that of the general population. Previously, we reported reduced immunogenicity to the standard-dose influenza vaccine in patients with central nervous system malignancy. In other poorly responding populations (eg, elderly patients), high-dose vaccination has improved efficacy and immunogenicity.

Methods

A prospective cohort study was designed to evaluate the immunogenicity of the Fluzone^® high-dose influenza vaccine in brain tumor patients. Data on diagnosis, active oncologic treatment, and immunologic status (eg, CD4 count, CD8 count, CD4:CD8 ratio) were collected. All patients received the high-dose vaccine (180 µg). Hemagglutination inhibition titers

SUBMITTER: Strowd RE 

PROVIDER: S-EPMC6655350 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature